We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

139 hedge funds and large institutions have $636M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

23% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 39

3% more funds holding

Funds holding: 135 → 139 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $663M → $636M (-$26.7M)

25% less call options, than puts

Call options by funds: $539K | Put options by funds: $723K

Holders
139
Holders Change
+4
Holders Change %
+2.96%
% of All Funds
3.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
48
Reduced
39
Closed
20
Calls
$539K
Puts
$723K
Net Calls
-$184K
Net Calls Change
-$1.81M

Top Buyers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
+$12.9M
2
Millennium Management
Millennium Management
New York
+$12.7M
3
TA
Teachers Advisors
New York
+$8.41M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$6.66M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.57M

Top Sellers

Rank Fund Capital Flow
1
VOYA Investment Management
VOYA Investment Management
Georgia
-$7.66M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.59M
3
State Street
State Street
Massachusetts
-$5.48M
4
PCM
Portolan Capital Management
Massachusetts
-$3.78M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
51
Allianz Asset Management
Germany
$778K – – –
NFA
52
Nationwide Fund Advisors
Ohio
$734K +$194K +2,761 +30%
TI
53
Trexquant Investment
Connecticut
$704K +$797K +11,325 New
HCM
54
Highbridge Capital Management
New York
$695K +$786K +11,173 New
Federated Hermes
55
Federated Hermes
Pennsylvania
$684K +$238K +3,377 +44%
PAG
56
Private Advisor Group
New Jersey
$657K +$122K +1,727 +20%
GBA
57
Garrison Bradford & Associates
New York
$653K – – –
FAM
58
Fred Alger Management
New York
$610K +$690K +9,811 New
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$608K +$20.4K +290 +3%
AIG
60
American International Group
New York
$509K -$1.05K -15 -0.2%
Wells Fargo
61
Wells Fargo
California
$502K +$201K +2,854 +55%
MIG
62
Mariner Investment Group
New York
$498K -$286K -4,067 -34%
Squarepoint
63
Squarepoint
New York
$486K +$551K +7,829 New
DekaBank Deutsche Girozentrale
64
DekaBank Deutsche Girozentrale
Germany
$457K +$8.94K +127 +2%
ARTA
65
A.R.T. Advisors
New York
$448K +$508K +7,219 New
WMSA
66
Weiss Multi-Strategy Advisers
New York
$435K +$35.8K +509 +8%
PA
67
Perceptive Advisors
New York
$395K +$447K +6,355 New
SW
68
SVB Wealth
Massachusetts
$384K -$177K -2,518 -29%
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$359K +$7.46K +106 +2%
Bank of America
70
Bank of America
North Carolina
$343K +$123K +1,745 +46%
OAM
71
Oxford Asset Management
United Kingdom
$342K +$378K +5,379 New
LPL Financial
72
LPL Financial
California
$338K +$170K +2,415 +79%
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$336K -$798K -11,347 -68%
PNC Financial Services Group
74
PNC Financial Services Group
Pennsylvania
$291K +$84.1K +1,195 +34%
Public Employees Retirement Association of Colorado
75
Public Employees Retirement Association of Colorado
Colorado
$284K – – –
1 2
3
4 5

MACK Hedge Fund Activity: Q4 2015 in Review

139 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2015, worth a combined $636M — down 4% from $663M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MACK positions and 20 closed out — a net gain of 5 holders — while 48 added to existing stakes and 39 trimmed.

The largest buyer was Putnam Investments, adding an estimated $12.9M. The largest seller was VOYA Investment Management, cutting an estimated $7.66M.

  • 139 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2015, up from 135 in Q3 2015.
  • Funds reported $636M of Merrimack Pharmaceuticals, Inc. stock for Q4 2015, down 4% quarter-over-quarter.
  • 25 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2015 and 20 closed out, a net change of +5 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2015 was Putnam Investments, an estimated $12.9M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2015 was VOYA Investment Management, an estimated $7.66M sold.

Based on aggregated 13F filings for Q4 2015.